Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Timigutuzumab |
Synonyms | |
Therapy Description |
Timigutuzumab is a second-generation ERBB2 (HER2) antibody derived from trastuzumab, which has potential antitumor activity and enhances antibody-dependent cellular cytotoxicity (PMID: 30018811). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Timigutuzumab | TrasGEX | HER2 (ERBB2) Antibody 72 | Timigutuzumab is a second-generation ERBB2 (HER2) antibody derived from trastuzumab, which has potential antitumor activity and enhances antibody-dependent cellular cytotoxicity (PMID: 30018811). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|